Abstract:
A novel class of acyl-derivatives of carnitine is disclosed wherein the acyl radical is either the radical of unsaturated organic acids (typically, acrylic acid) or the radical of saturated organic acids substituted with tert-alkyl, cycloalkyl, cycloalkenyl, alkoxyl, heterocyclic and carboalkoxylradicals, or with aldehyde or hydroxy groups. These acyl-derivatives of carnitine are useful therapeutical agents in the treatment of cardiac disorders, hyperlipidaemias and hyperlipoproteinaemias.
Abstract:
A novel class of alkoxy-acyl carnitines, wherein the alkoxy-acyl radical has from 4 to 6 carbon atoms (tipically: methoxypropionyl, ethoxypropionyl and propoxyacetyl) is prepared by reacting a solution of a carnitine salt in an organic solvent with an alkoxy-acyl halogenide, thus obtaining the corresponding salt of alkoxy-acyl carnitine. By eluting an aqueous solution of this salt through a column of an ion exchange resin activated in Cl.sup.- or Br.sup.- form, the chloride or bromide of alkoxy-acyl carnitine is obtained. The alkoxy-acyl carnitines are therapeutically effective in the treatment of cardiac disorders, hyperlipidaemias and hyperlipoproteinaemias.
Abstract:
Carnitine derivatives of formula (I) are described in racemic and/or optically active form, as well as the process for their preparation and their use as pharmaceutical anti-angina active ingredients for the treatment of ischaemic heart disease. Also described is a process for producing the (R)-carnitine enantiomer from (S)-carnitine (or vice versa), using the derivatives of formula (I).
Abstract:
Amides of carnitine or acyl-carnitines having general formula: ##STR1## wherein X.sup.- is a halogen anion, e.g. the chloride anionR is either hydrogen or an acyl radical, such as acetyl, propionyl or butyryl; andY is the residue of an optically active esterified amino-acid (e.g. the residue of L-phenylglycine methyl ester, ##STR2## are prepared by either (a) directly condensing D,L-carnitine (or acyl-D,L-carnitine) with an ester of an optically active aminoacid, or (b) preparing the acid halogenide of D,L-carnitine or acyl-D,L-carnitine and subsequently condensing it with an ester of an optically active aminoacid.The mixture of the diastereoisomer amides thus obtained is resolved by fractional crystallization from organic solvents into the respective separated diastereoisomers.These optically active amides are useful therapeutic agents for treating cardiac disorders, hyperlipidaemias and hyperlipoproteinaemias and, furthermore, can be hydrolyzed with procedures known per se into L-carnitine and D-carnitine, respectively.
Abstract:
A two-step process for manufacturing d,l-.beta.-benzoylamino-isobutyric acid is disclosed, wherein in the first step benzamide is reacted with methacrylonitrile in the presence of an alkaline catalyst in an anhydrous solvent medium at atmospheric pressure, thus obtaining d,l-.beta.-benzoylamino-isobutyronitrile, which, in the second process step, without necessarily being previously crystallized is directly hydrolyzed to d,l-.beta.-benzoylamino-isobutyric acid.
Abstract:
A process for the production of (R)- or (S)-aminocarnitine starting respectively from (R)- or (S)-nitryloxycarnitine, through the formation and hydrogenation of the azidocarnitine intermediate with the same absolute configuration is described. (R)-aminocarnitine inner salt is obtained after purification, which is then converted into non-deliquescent salts. Also a process for the preparation of derivatives of (R)- and (S)-aminocarnitine, in particular acylayed or ureic derivatives, having known pharmacological properties, starting from (R)- and (S)-aminocarnitine salts, releasing the aminic function in situ.
Abstract:
A new, more efficient and highly stereospecific process is described for the preparation of compounds with general formula (R)-(I) and of absolute configuration (R), where the groups M, W, Q and Q1 are as defined in the description, starting from compounds of absolute configuration (S) by hydrolysis, in the presence of acids, of the corresponding esterified derivatives. The (R)-(I) products obtained with the process described herein are chiral synthons useful for the production of enanthiomerically pure drugs. The preparation of (R)-carnitine is also provided.
Abstract:
Novel acyl-derivatives of the .beta.-hydroxy-.gamma.-butyrobetaine are disclosed (typically pyruvyl carnitine hydrochloride) which are useful therapeutic agents in the treatment of cardiac disorders, hyperlipidoemias and hyperlipoproteinemias.
Abstract:
A Process for Preparing L-(-)-carnitine is disclosed which comprises acylating D-(+)-carnitinenitrile or D-(+)-carnitineamide to their respective acyl derivatives which, via acid hydrolysis, yield D-(+)-carnitine which is converted to the lactone of L-(-)-carnitine. The lactone when in base yields L-(-)-carnitine.
Abstract:
There is described an electrolytic cell and a process for removing the halide or other anion from an organic salt having as general formula A+X--, wherein A+ is an organic cation and X-- is a halide or other anion. Typical compounds of this type are the hydrohalides of nitrogen bases or other salts or hydrosalts of such bases or compounds notably salts (hydrohalides) of quaternary ammonium bases or of amines or amides. However the process herein contemplated may be applied to the removal of anions, e.g. chloride, which are present as an impurity or in combination with the organic compound.